EPHX2 and Alzheimer disease: Thus, we inferred that the so far unexploreddual targeting ofsEH and AChE might open a new avenue for AD treatment as it shouldresult in cumulative effects for reducing neuroinflammation and preventingcognitive impairment, i.e., disease-modifying plus symptomatic effects.As a proof of concept, here, we report the design, synthesis, in vitrobiological activities, neurotoxicity and DMPK properties, molecularmodeling, and an in vivo efficacy study in a mouse model of AD ofa class of dual inhibitors of sEH and AChE.